Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 3/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 4/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578320 | 0.78 | ABL1 (0.37) | ABL1FGFR1DDR2BRAFRORC | |
| SCHEMBL5812270 | 0.74 | ABL1 (0.34) | ABL1ATRFGFR1BRAFRORC | |
| SCHEMBL5808054 | 0.74 | ABL1 (0.34) | ABL1HDAC4HDAC6ATRBRAF | |
| SCHEMBL5821921 | 0.74 | CNR2 (0.35) | ABL1HDAC4HDAC6ATRBRAF | |
| SCHEMBL5578291 | 0.74 | ELANE (0.37) | ABL1BRAF | |
| SCHEMBL1645164 | 0.70 | ATR (0.38) | ABL1ATRBRAF | |
| SCHEMBL2382993 | 0.70 | ATR (0.36) | ABL1ATRFGFR1DDR2BRAF | |
| SCHEMBL14511713 | 0.69 | CCNA2 (0.38) | ABL1FGFR1DDR2BRAF | |
| SCHEMBL30861007 | 0.69 | BRD9 (0.37) | ATRRORC | |
| SCHEMBL4129018 | 0.68 | NAMPT (0.36) | ABL1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006070202-A1 | PYRAZOLE DERIVATIVES HAVING KINASE MODULATING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |